Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director | March 21, 2024 | March 25, 2024 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date March 21, 2024 · Filed March 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,703 |
Ending reported balance
After 2024-03-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-21 · Exercise / conversion · Acquired 23,491 · Balance 54,908 Row 2 · 2024-03-21 · Sale · Disposed 19,205 · Balance 35,703 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.57 · Expires 2024-05-24 | Direct | 0 |
Reported balance
After 2024-03-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-21 · Exercise / conversion · Disposed 23,491 · Balance 0 F3: The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3: The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017.
VERTEX PHARMACEUTICALS INC / MA
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 65.458 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 31.56 · Balance 65.458 F1: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2018 Filed May 25, 2018 00:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 31,167 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000103 · wf-form4_152720762288163.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,167 Underlying: Common Stock · 31,167 shares Expires 2025-05-23 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0000939767-18-000054 · wf-form4_152409666066391.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $20.25 | $303,750.00 |
DisclosureSEC source: 0000939767-18-000054 · wf-form4_152409666066391.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2017. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.03 to $20.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $11.66 | $174,900.00 |
DisclosureSEC source: 0000939767-18-000054 · wf-form4_152409666066391.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 11,500 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · derivative · entry 6 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Option (right to buy) · 11,500 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2009. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 11,500 | $30.00 | $345,000.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · nonDerivative · entry 4 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 26, 2017. Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 11,500 | $7.97 | $91,655.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · nonDerivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · derivative · entry 5 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Option (right to buy) · 3,500 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2009. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 3,500 | $31.29 | $109,515.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 26, 2017. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.51. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 08, 2018 Filed Jan 11, 2018 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 3,500 | $7.97 | $27,895.00 |
DisclosureSEC source: 0000939767-18-000002 · wf-form4_151563042764056.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,320 | $0.00 Strike: $125.11 | $0.00 |
DisclosureSEC source: 0001209191-17-038859 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 Underlying: Common Stock · 5,320 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 06/08/2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038859 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,199 F1 · shares: Restricted stock unit award that vests in four annual installments from 6/08/2017. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000110 · wf-form4_149584603869354.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| December 09, 2016 Filed Dec 10, 2016 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0000939767-16-000290 · wf-form4_148133172396557.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2008. Read SEC document |
| December 09, 2016 Filed Dec 10, 2016 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 7,832 | $16.90 | $132,360.80 |
DisclosureSEC source: 0000939767-16-000290 · wf-form4_148133172396557.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.9001 to $16.9006. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| December 09, 2016 Filed Dec 10, 2016 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 10,000 | $10.53 | $105,300.00 |
DisclosureSEC source: 0000939767-16-000290 · wf-form4_148133172396557.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,638 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.